FDA Approves Genentech’s Kadcyla, the 1st ADC for Treating HER2-Positive

LONDON - March 15, 2013 - PRLog -- Genentech have recently announced FDA approval for for the treatment of people with HER2-positive metastatic breast cancer (mBC). According to Bloomberg this is now the fourth medicine from Genentech to receive FDA approval for people with advanced cancers within the past two years.

To hear more on Genetech latest developments, you can meet them at SMi’s ADC Summit 2013 taking place 20-21 May, London.

Conference sessions will include Genetechs presentation on Novel linker-drugs for ADC'S.

Other speakers at SMi’s ADC Summit will include:

Alastair Lawson,  VP Structural Biology, UCB
Charles Dumontet, Department Head, INSERM
John Hartley, Head of Biology, Spirogen
Kendall Morrison, Director of Protein Technologies, Agensys (an affiliate of Astellas)
Robert Hollingsworth, Senior Director, Medimmune Inc
Thomas Pillow, Scientist, Genentech
Thomas Chittenden, Executive Director, Research, ImmunoGen

ADC 2013 promises to show attendees how the latest technologies and clinical data have transformed the industry.  Topics covered will include conjugate chemistry, target selection, novel payload deliveries, future ADC pipelines and regulatory issues.

For further information please contact John Collins at jcollins@smi-online.co.uk or go online at:

http://www.smi-online.co.uk/goto/adcsummit43.asp